Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO John Kollins will present at the SVB Securities Global Biopharma Conference from February 14-16, 2023. Kollins is scheduled to speak on February 16 at 1:40 PM ET, with a live webcast available. Satsuma is developing STS101, a novel nasal powder formulation of dihydroergotamine, aimed at providing an improved acute treatment for migraines. STS101 is designed for quick self-administration, with advantages over existing DHE products. The company seeks to enhance therapeutic options for migraine patients, addressing limitations of current treatments.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16. Mr. Kollins will also host virtual one-on-one meetings with investors.
Mr. Kollins is scheduled to present at 1:40pm ET on Thursday, February 16. A live webcast of the presentation can be accessed here.
To arrange a one-on-one meeting, please contact your SVB Securities representative.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for robust efficacy, and sustained DHE plasma levels over time with low dose-to-dose variability. DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients. However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring an easy-to-carry and easy-to-use dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
FAQ
What is Satsuma Pharmaceuticals planning to present at the SVB Securities Global Biopharma Conference?
When will John Kollins present at the SVB Securities Global Biopharma Conference?
What is STS101 and its significance for migraine treatment?
How does STS101 compare to existing migraine treatments?
Where can I watch the Satsuma Pharmaceuticals presentation?
